Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
Enzolytics Inc. (OTC PINK:ENZC) has announced its full support for Sagaliam Acquisition Corp's (SAGA) efforts to counter false claims made by NIKA Pharmaceutical and its CEO, Dimtar Savov. The dispute centers around patents for an Immunotherapy treatment of HIV/AIDS, which Enzolytics asserts are rightfully owned by Harry H. Zhabilov and the Zhabilov Trust. Virogentics, Inc., a wholly-owned subsidiary of Sagaliam, is stated to be the exclusive license holder of this intellectual property.
Steve Sharabura, Interim CEO of Enzolytics, emphasized the company's commitment to protecting shareholder value and ending what they describe as a 'travesty'. The press release highlights previous legal actions in US and Bulgarian courts, where Mr. Savov reportedly lost civil court cases and defaulted on licensing agreements.
Enzolytics Inc. (OTC PINK:ENZC) ha annunciato il suo pieno sostegno agli sforzi di Sagaliam Acquisition Corp (SAGA) per contrastare le false affermazioni di NIKA Pharmaceutical e del suo CEO, Dimtar Savov. La disputa riguarda i brevetti per un trattamento immunoterapico per HIV/AIDS, che Enzolytics sostiene siano legittimamente di proprietà di Harry H. Zhabilov e del Zhabilov Trust. Virogentics, Inc., una controllata interamente di Sagaliam, è dichiarata essere l'unica titolare della licenza di questa proprietà intellettuale.
Steve Sharabura, CEO ad interim di Enzolytics, ha sottolineato l'impegno dell'azienda nella protezione del valore per gli azionisti e nella conclusione di quello che definiscono un 'travesty'. Il comunicato stampa mette in evidenza precedenti azioni legali nei tribunali statunitensi e bulgari, dove il signor Savov ha perso casi civili e ha inadempiuto agli accordi di licenza.
Enzolytics Inc. (OTC PINK:ENZC) ha anunciado su total apoyo a los esfuerzos de Sagaliam Acquisition Corp (SAGA) para contrarrestar las afirmaciones falsas realizadas por NIKA Pharmaceutical y su CEO, Dimtar Savov. La disputa se centra en patentes para un tratamiento de inmunoterapia para el VIH/SIDA, que Enzolytics afirma que pertenecen legítimamente a Harry H. Zhabilov y al Zhabilov Trust. Virogentics, Inc., una subsidiaria de propiedad total de Sagaliam, se afirma que es el titular exclusivo de la licencia de esta propiedad intelectual.
Steve Sharabura, CEO interino de Enzolytics, enfatizó el compromiso de la compañía con la protección del valor para los accionistas y el fin de lo que describen como una 'infamia'. El comunicado de prensa destaca acciones legales anteriores en tribunales de EE. UU. y búlgaros, donde el Sr. Savov supuestamente perdió casos en cortes civiles y no cumplió con los acuerdos de licencia.
Enzolytics Inc. (OTC PINK:ENZC)는 NIKA Pharmaceutical과 CEO인 Dimtar Savov가 제기한 허위 주장에 맞서기 위해 Sagaliam Acquisition Corp (SAGA)의 모든 노력을 지지한다고 발표했습니다. 이 분쟁은 HIV/AIDS 면역치료 치료법에 대한 특허와 관련이 있으며, Enzolytics는 이 특허가 Harry H. Zhabilov와 Zhabilov Trust의 정당한 소유라고 주장합니다. Virogentics, Inc.는 Sagaliam의 전액 출자 자회사로, 이 지식 재산의 독점 라이선스 보유자로 알려져 있습니다.
Enzolytics의 임시 CEO인 Steve Sharabura는 회사가 주주 가치를 보호하고 그들이 '불법'이라고 표현하는 상황을 종식시키기 위해 헌신하고 있음을 강조했습니다. 보도자료에는 Savov 씨가 미국 및 불가리아 법원에서 민사 소송에서 패소하고 라이선스 계약을 이행하지 않았다는 이전 법적 조치가 강조되었습니다.
Enzolytics Inc. (OTC PINK:ENZC) a annoncé son soutien total aux efforts de Sagaliam Acquisition Corp (SAGA) pour contrer les fausses allégations faites par NIKA Pharmaceutical et son PDG, Dimtar Savov. Le litige porte sur des brevets pour un traitement d'immunothérapie pour le VIH/SIDA, que Enzolytics prétend appartenir légitimement à Harry H. Zhabilov et à la Zhabilov Trust. Virogentics, Inc., une filiale à part entière de Sagaliam, est désignée comme le détenteur exclusif de la licence de cette propriété intellectuelle.
Steve Sharabura, PDG par intérim d'Enzolytics, a souligné l'engagement de l'entreprise à protéger la valeur pour les actionnaires et à mettre fin à ce qu'ils décrivent comme une 'injustice'. Le communiqué de presse met en lumière des actions judiciaires antérieures dans des tribunaux américains et bulgares, où M. Savov aurait perdu des affaires civiles et fait défaut sur des accords de licence.
Enzolytics Inc. (OTC PINK:ENZC) hat seine volle Unterstützung für die Bemühungen von Sagaliam Acquisition Corp (SAGA) angekündigt, um falschen Ansprüchen von NIKA Pharmaceutical und deren CEO, Dimtar Savov, entgegenzuwirken. Der Streit dreht sich um Patente für eine Immuntherapie-Behandlung von HIV/AIDS, die Enzolytics zu Recht Harry H. Zhabilov und dem Zhabilov Trust zuspricht. Virogentics, Inc., eine hundertprozentige Tochtergesellschaft von Sagaliam, wird als exklusiver Lizenzinhaber dieses geistigen Eigentums angegeben.
Steve Sharabura, Interim-CEO von Enzolytics, betonte das Engagement des Unternehmens, den Wert für die Aktionäre zu schützen und das zu beenden, was sie als 'Ungerechtigkeit' beschreiben. Die Pressemitteilung hebt frühere rechtliche Schritte vor US-amerikanischen und bulgarischen Gerichten hervor, bei denen Herr Savov offenbar Zivilsachen verloren und gegen Lizenzvereinbarungen verstoßen hat.
- Enzolytics is aligning with Sagaliam to protect intellectual property rights
- The company is taking a proactive stance to defend shareholder value
- Ongoing legal disputes may divert resources and management attention
- False claims by competitors could potentially harm investor perception and stock performance
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and its CEO, Dimtar Savov, falsely claiming rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has, since defaulting on licensing agreements and losses in civil court actions in the US and Bulgarian court systems, erroneously and maliciously asserted claims to ITV-1 in his attempt to mislead the investing public and to harm the shareholder value of SAGA as well as the Company. The exclusive license holder of this intellectual property is Virogentics, Inc., a wholly owned subsidiary of Sagaliam.
Sagaliam press release issued on July 25, 2017: https://finance.yahoo.com/news/sagalium-responds-competitor-false-misleading-204600512.html
Steve Sharabura, Interim CEO of Enzolytics, commented, "I and the Board of Directors are steadfastly aligned with Sagaliam to bring to an end this travesty and the protection of both entities' shareholder value."
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to a sales, marketing and distribution entity focusing on medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
SOURCE: Enzolytics, Inc.
View the original press release on accesswire.com
FAQ
What is the dispute between Enzolytics (ENZC) and NIKA Pharmaceutical about?
Who holds the exclusive license for the HIV/AIDS Immunotherapy treatment patents related to Enzolytics (ENZC)?
How is Enzolytics (ENZC) responding to the alleged false claims by NIKA Pharmaceutical?
What legal actions have been taken regarding the patent dispute involving Enzolytics (ENZC)?
